Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia

Gerald L Denardo, Kathleen R. Lamborn, Desirée S. Goldstein, Linda A. Kroger, Sally J. DeNardo

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

BACKGROUND. Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients treated with radiolabeled Lym-1. METHODS. Fifty- seven patients with NHL (52) or CLL (5) were treated with radiolabeled Lym- 1 antibody between 1985 and 1994. Influence of response to treatment on survival was examined directly and was also adjusted for other factors previously found to be significant predictors of survival. A multivariate model that was based on baseline Karnofsky performance status (KPS) and serum lactic dehydrogenase (LDH) predicted response and survival and was used to define risk groups. Proportional-hazards, Kaplan-Meier, and Landmark models were used to evaluate parameters for their ability to predict outcome. RESULTS. By using a proportional-hazards model with response as a time-dependent variable, overall response (P < 0.001) and complete response (P = 0.006) were predictive of increased survival in univariate analyses. Overall response continued to be significant (P = 0.02) in multivariate analyses, even when risk groups that also predicted survival were included. Median survival of responders was 84 weeks, whereas that of nonresponders was 22 weeks when the Landmark method, based on response status at 16 weeks from start of therapy, was used to generate survival curves. CONCLUSIONS. Response to treatment with radiolabeled Lym- 1 was associated with increased survival, even when adjusted for baseline clinical parameters that also predicted for survival. The results provide the first unbiased evidence for survival effects of RIT in patients.

Original languageEnglish (US)
Pages (from-to)2706-2711
Number of pages6
JournalCancer
Volume80
Issue number12 SUPPL.
StatePublished - Dec 15 1997

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Survival
Therapeutics
Radioimmunotherapy
Karnofsky Performance Status
Proportional Hazards Models
Oxidoreductases
Milk
Multivariate Analysis

Keywords

  • Leukemia
  • Lym-1
  • Lymphoma
  • Radioimmunotherapy
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Denardo, G. L., Lamborn, K. R., Goldstein, D. S., Kroger, L. A., & DeNardo, S. J. (1997). Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer, 80(12 SUPPL.), 2706-2711.

Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia. / Denardo, Gerald L; Lamborn, Kathleen R.; Goldstein, Desirée S.; Kroger, Linda A.; DeNardo, Sally J.

In: Cancer, Vol. 80, No. 12 SUPPL., 15.12.1997, p. 2706-2711.

Research output: Contribution to journalArticle

Denardo, GL, Lamborn, KR, Goldstein, DS, Kroger, LA & DeNardo, SJ 1997, 'Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia', Cancer, vol. 80, no. 12 SUPPL., pp. 2706-2711.
Denardo, Gerald L ; Lamborn, Kathleen R. ; Goldstein, Desirée S. ; Kroger, Linda A. ; DeNardo, Sally J. / Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia. In: Cancer. 1997 ; Vol. 80, No. 12 SUPPL. pp. 2706-2711.
@article{33aeb501aef24922a02ec1c699229954,
title = "Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia",
abstract = "BACKGROUND. Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients treated with radiolabeled Lym-1. METHODS. Fifty- seven patients with NHL (52) or CLL (5) were treated with radiolabeled Lym- 1 antibody between 1985 and 1994. Influence of response to treatment on survival was examined directly and was also adjusted for other factors previously found to be significant predictors of survival. A multivariate model that was based on baseline Karnofsky performance status (KPS) and serum lactic dehydrogenase (LDH) predicted response and survival and was used to define risk groups. Proportional-hazards, Kaplan-Meier, and Landmark models were used to evaluate parameters for their ability to predict outcome. RESULTS. By using a proportional-hazards model with response as a time-dependent variable, overall response (P < 0.001) and complete response (P = 0.006) were predictive of increased survival in univariate analyses. Overall response continued to be significant (P = 0.02) in multivariate analyses, even when risk groups that also predicted survival were included. Median survival of responders was 84 weeks, whereas that of nonresponders was 22 weeks when the Landmark method, based on response status at 16 weeks from start of therapy, was used to generate survival curves. CONCLUSIONS. Response to treatment with radiolabeled Lym- 1 was associated with increased survival, even when adjusted for baseline clinical parameters that also predicted for survival. The results provide the first unbiased evidence for survival effects of RIT in patients.",
keywords = "Leukemia, Lym-1, Lymphoma, Radioimmunotherapy, Survival",
author = "Denardo, {Gerald L} and Lamborn, {Kathleen R.} and Goldstein, {Desir{\'e}e S.} and Kroger, {Linda A.} and DeNardo, {Sally J.}",
year = "1997",
month = "12",
day = "15",
language = "English (US)",
volume = "80",
pages = "2706--2711",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Increased survival associated with radiolabeled Lym-1 therapy for non- Hodgkin's lymphoma and chronic lymphocytic leukemia

AU - Denardo, Gerald L

AU - Lamborn, Kathleen R.

AU - Goldstein, Desirée S.

AU - Kroger, Linda A.

AU - DeNardo, Sally J.

PY - 1997/12/15

Y1 - 1997/12/15

N2 - BACKGROUND. Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients treated with radiolabeled Lym-1. METHODS. Fifty- seven patients with NHL (52) or CLL (5) were treated with radiolabeled Lym- 1 antibody between 1985 and 1994. Influence of response to treatment on survival was examined directly and was also adjusted for other factors previously found to be significant predictors of survival. A multivariate model that was based on baseline Karnofsky performance status (KPS) and serum lactic dehydrogenase (LDH) predicted response and survival and was used to define risk groups. Proportional-hazards, Kaplan-Meier, and Landmark models were used to evaluate parameters for their ability to predict outcome. RESULTS. By using a proportional-hazards model with response as a time-dependent variable, overall response (P < 0.001) and complete response (P = 0.006) were predictive of increased survival in univariate analyses. Overall response continued to be significant (P = 0.02) in multivariate analyses, even when risk groups that also predicted survival were included. Median survival of responders was 84 weeks, whereas that of nonresponders was 22 weeks when the Landmark method, based on response status at 16 weeks from start of therapy, was used to generate survival curves. CONCLUSIONS. Response to treatment with radiolabeled Lym- 1 was associated with increased survival, even when adjusted for baseline clinical parameters that also predicted for survival. The results provide the first unbiased evidence for survival effects of RIT in patients.

AB - BACKGROUND. Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients treated with radiolabeled Lym-1. METHODS. Fifty- seven patients with NHL (52) or CLL (5) were treated with radiolabeled Lym- 1 antibody between 1985 and 1994. Influence of response to treatment on survival was examined directly and was also adjusted for other factors previously found to be significant predictors of survival. A multivariate model that was based on baseline Karnofsky performance status (KPS) and serum lactic dehydrogenase (LDH) predicted response and survival and was used to define risk groups. Proportional-hazards, Kaplan-Meier, and Landmark models were used to evaluate parameters for their ability to predict outcome. RESULTS. By using a proportional-hazards model with response as a time-dependent variable, overall response (P < 0.001) and complete response (P = 0.006) were predictive of increased survival in univariate analyses. Overall response continued to be significant (P = 0.02) in multivariate analyses, even when risk groups that also predicted survival were included. Median survival of responders was 84 weeks, whereas that of nonresponders was 22 weeks when the Landmark method, based on response status at 16 weeks from start of therapy, was used to generate survival curves. CONCLUSIONS. Response to treatment with radiolabeled Lym- 1 was associated with increased survival, even when adjusted for baseline clinical parameters that also predicted for survival. The results provide the first unbiased evidence for survival effects of RIT in patients.

KW - Leukemia

KW - Lym-1

KW - Lymphoma

KW - Radioimmunotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0031471674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031471674&partnerID=8YFLogxK

M3 - Article

C2 - 9406728

AN - SCOPUS:0031471674

VL - 80

SP - 2706

EP - 2711

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12 SUPPL.

ER -